Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

1.430 +0.030 (+2.14%)
Streaming Delayed Price Updated: 10:09 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 Next >
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
Via Investor Brand Network
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
Via Investor Brand Network
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
From atai Life Sciences
Via GlobeNewswire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.